Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2023) 142 (Supplement 1): 689.

https://doi.org/10.1182/blood-2023-189125

Published: 2023

Journal Articles

Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim

Adrian Newland, MA, FRCP, FRCPath, James B. Bussel, MD, Robert Bird, FRACP, FRCP, FRCPA, MBBS, MRCP, Donald M. Arnold, MD MSc, FRCPC, Craig M. Kessler, Jiří Mayer, Monica Tejeda Romero, Ann Janssens, Kejia Wang, PhD, Melissa Jeanne Eisen, MD

Blood (2018) 132 (Supplement 1): 735.

https://doi.org/10.1182/blood-2018-99-109791

Published: 2018

Journal Articles

Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year

David J Kuter, MD DPhil, Adrian Newland, Beng H Chong, MBBS, PhD, Francesco Rodeghiero, MD, Monica Tejeda Romero, Ingrid Pabinger, MD, Yuqi Chen, Kejia Wang, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 1055.

https://doi.org/10.1182/blood.V130.Suppl_1.1055.1055

Published: 2017

Journal Articles

Treatment, Platelet Count Pattern and Comorbidities Among Primary Immune Thrombocytopenia (ITP) Patients Seen in Routine Clinical Practice: Data from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry

Umesh Doobaree, MSc, RN, BSc, Lara Wyatt, Raghava Nandigam, Adrian Newland, Andrew Provan

Blood (2017) 130 (Supplement 1): 3622.

https://doi.org/10.1182/blood.V130.Suppl_1.3622.3622

Published: 2017

Journal Articles

A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim

Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Amelia Orejudos, Angela Lopez

Blood (2014) 124 (21): 2775.

https://doi.org/10.1182/blood.V124.21.2775.2775

Published: 2014

Journal Articles

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Roberto Stasi, MD, PhD, Adrian Newland, Bertrand Godeau, Victor Priego, MD, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Catherine Jia, Angela Lopez

Blood (2013) 122 (21): 1074.

https://doi.org/10.1182/blood.V122.21.1074.1074

Published: 2013

Journal Articles

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group

Blood (2013) 121 (14): 2596–2606.

https://doi.org/10.1182/blood-2012-07-442392

Published: 2013

Includes: Supplemental data

Journal Articles

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

David J. Kuter, MD, DPhil, James B. Bussel, MD, Adrian Newland, FRCP, Jeffrey S. Wasser, MD, Roger M Lyons, MD, James N. George, MD, Gail Macik, MD, Kun Nie, Susie Jun

Blood (2010) 116 (21): 68.

https://doi.org/10.1182/blood.V116.21.68.68

Published: 2010

Journal Articles

Autologous 111 In-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry.

Ameet Sarpatwari, M.Phil, Drew Provan, MD, Ravin Sobnack, PhD, Sebhat Erqou, MD, M.Phil, F. W. David Tai, BSc., Simon Sanderson, MD, Adrian Newland, MD, FRCP

Blood (2009) 114 (22): 2406.

https://doi.org/10.1182/blood.V114.22.2406.2406

Published: 2009

Journal Articles

Disease Progression, Treatment Effectiveness, and Co-Morbid Burden Among Adult Patients with Primary Immune Thrombocytopenia (ITP): Results From the United Kingdom Registry.

Ameet Sarpatwari, M.Phil, Dimitri Bennett, MD, MPH, Adrian Newland, MD, FRCP, Simon Sanderson, MD, Drew Provan, MD

Blood (2009) 114 (22): 4457.

https://doi.org/10.1182/blood.V114.22.4457.4457

Published: 2009

Journal Articles

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

James B. Bussel, MD, David J Kuter, MD, DPhil, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Jeffrey Wasser, MD, Paul Chang, Kun Nie, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 681.

https://doi.org/10.1182/blood.V114.22.681.681

Published: 2009

Journal Articles

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

Roberto Stasi, Ameet Sarpatwari, Jodi B. Segal, John Osborn, Maria Laura Evangelista, Nichola Cooper, Drew Provan, Adrian Newland, Sergio Amadori, James B. Bussel

Blood (2009) 113 (6): 1231–1240.

https://doi.org/10.1182/blood-2008-07-167155

Published: 2009

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

Journal Articles

Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom.

Ameet Sarpatwari, MPhil, Shirley Watson, Howard Anderson, Drew Provan, MD, Adrian Newland, MD, FRCP

Blood (2008) 112 (11): 3435.

https://doi.org/10.1182/blood.V112.11.3435.3435

Published: 2008

Journal Articles

Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research Database.

Ameet Sarpatwari, MPhil, Dimitri Bennett, MD, MPH, John W Logie, PhD, Amit Shukla, BSc, Kathleen J Beach, MD, MPH, Adrian Newland, MD, FRCP, Simon Sanderson, MD, Drew Provan, MD

Blood (2008) 112 (11): 3401.

https://doi.org/10.1182/blood.V112.11.3401.3401

Published: 2008

Journal Articles

Using CD160 as a Novel Approach to the Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL).

Timothy Farren, BSc (Hons), Jerome Giustiniani, PhD, Ulrika Johansson, PhD, Christina Lim, RN, Gemma Athorn, MSc, Adrian Newland, MD, Marion Macey, PhD, Samir Agrawal, MD, PhD

Blood (2007) 110 (11): 2036.

https://doi.org/10.1182/blood.V110.11.2036.2036

Published: 2007

Journal Articles

Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.

Vinod Pullarkat, Terry B. Gernsheimer, J. Th. M. de Wolf, Troy H. Guthrie, Jr., Adrian Newland, Jeffrey S. Wasser, Solomon I. Hamburg, Sue Gao, Ron Stewart, Janet L. Nichol

Blood (2007) 110 (11): 1304.

https://doi.org/10.1182/blood.V110.11.1304.1304

Published: 2007

Journal Articles

An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP).

Adrian Newland, MD, Marie T. Caulier, MD, Martin R. Schipperus, MD, Maria Kappers-Klunne, MD, Bruno R. Varet, Karen Watkins, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS

Blood (2004) 104 (11): 2058.

https://doi.org/10.1182/blood.V104.11.2058.2058

Published: 2004

Journal Articles

An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.

Louis M. Aledort, MD, Abdulgabar Salama, MD, Lidia Kovaleva, MD, Tadeusz Robak, MD, Benjamin Brenner, MD, Adrian Newland, MD, Simon Davies, MD, Diane J. Nugent, MD, Alphonse Hubsch, DVM, Irmgard Andresen, MD, Othmar Zenker, MD

Blood (2004) 104 (11): 3943.

https://doi.org/10.1182/blood.V104.11.3943.3943

Published: 2004

NARROW

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim

Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year

Treatment, Platelet Count Pattern and Comorbidities Among Primary Immune Thrombocytopenia (ITP) Patients Seen in Routine Clinical Practice: Data from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry

A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

Autologous 111 In-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry.

Disease Progression, Treatment Effectiveness, and Co-Morbid Burden Among Adult Patients with Primary Immune Thrombocytopenia (ITP): Results From the United Kingdom Registry.

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom.

Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research Database.

Using CD160 as a Novel Approach to the Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL).

Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.

An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP).

An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only